Clinical trials of alirocumab - TrialResults-center.org

Praluent - SAR236553 - monoclonal antibody REGN727 - REGN727 monoclonal antibody - alirocumab

Trial	Studied trt	Control trt	ROB	Trial result	death from all causes as adverse event
Group by... in first in second in third	Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation			Global trial result Main results All results All result tag NCT results	Numeric bar chart forest plot medians
cardiovascular prevention
ODYSSEY OPTIONS I	alirocumab	ezetimibe (on top statin)		negative
ODYSSEY OPTIONS II	alirocumab	ezetimibe (on top statin)		negative
ODYSSEY MONO NCT	alirocumab	ezetimibe alone	Low risk of bias	negative
ODYSSEY Long-Term, 2015 NCT	alirocumab	placebo (on top statins)	Exploratory	suggesting
ODYSSEY Alternative NCT	alirocumab	placebo (on top statins)	Low risk of bias	negative
ODYSSEY OUTCOMES, 2018 NCT	alirocumab	placebo (on top statins)	Low risk of bias	conclusive
ODYSSEY FH 1 NCT	alirocumab	placebo (on top statins)	Low risk of bias	-
ODYSSEY FH 2 NCT	alirocumab	placebo (on top statins)	Low risk of bias	-
ODYSSEY HIGH FH NCT	alirocumab	placebo (on top statins)		negative
ODYSSEY COMBO NCT	alirocumab	placebo (on top statins)	Low risk of bias	negative
ODYSSEY COMBO II NCT	alirocumab	placebo (on top statins)	Low risk of bias	negative

Alirocumab PCSK9 Inhibitors systematic review meta-analysis network meta-analysis